Results 161 to 170 of about 21,815 (182)
PCAT1 Supports Partial AR-V7 Function and Promotes Enzalutamide Resistance in Prostate Cancer. [PDF]
Li T, Li R, Hao J, Yu J, Niu Y.
europepmc +1 more source
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer. [PDF]
Agarwal N +20 more
europepmc +1 more source
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer [PDF]
BACKGROUND: Preliminary trial results showed that enzalutamide significantly improved metastasis-free survival among men who had nonmetastatic, castration-resistant prostate cancer and rapidly increasing prostate-specific antigen (PSA) levels while ...
Neal Shore +2 more
exaly +2 more sources
Enzalutamide in Metastatic Prostate Cancer Before Chemotherapy [PDF]
BACKGROUND: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with metastatic castration-resistant prostate cancer in whom the disease has progressed after chemotherapy.
Anthony M Joshua +2 more
exaly +6 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Enzalutamide With Standard First-Line Therapy in Metastatic Prostate Cancer
New England Journal of Medicine, 2019Anthony M Joshua +2 more
exaly

